Published: Jun 03, 2021
COLUMBUS, Ohio (BUSINESS WIRE) Forge Biologics, a gene therapy-focused contract development and manufacturing organization (CDMO), announced today the appointment of John Maslowski to the newly created role of Chief Commercial Officer. Mr. Maslowski brings significant gene therapy manufacturing and development experience to Forge as the Company has expanded its cGMP AAV manufacturing capabilities, including process and analytical development. As CCO, Mr. Maslowski will lead the Marketing, Sales, and Client Development departments to support our partners and clients on their path towards commercializing gene therapies.
John Maslowski, Chief Commercial Officer (Photo: Business Wire)
“We are excited to have John join the leadership team at such an important inflection point in the growth of Forge,” said Timothy J. Miller, Ph.D., CEO, President and Co-Founder of Forge Biologics. “John is a seasoned biotech executive, bringing over 20 years o
/PRNewswire/ miR Scientific, LLC, a healthcare company dedicated to transforming global cancer management by providing early and highly accurate detection,.
Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the
Time: 9:30 AM (EST)
Webcast or external link of the company presentations will be available under Events & Presentations in the Investors Relations section of CASI s website. Archived replays will be available for approximately 30 days following the event.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. The Company intends to execute its plan to become a leader by launching medicines in the greater China market leveraging the Company s China-based regulatory and commercial competencies and its global drug development expertise. The Company s operations in China are conducted through its wholly-owned subsidiary, CAS
iTeos to Present at the Jefferies Virtual Healthcare ConferenceCAMBRIDGE, Mass. and GOSSELIES, Belgium, May 26, 2021 (GLOBE NEWSWIRE) iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-onc.